Enanta Pharmaceuticals appoints new board member
Dr. Russell will also serve as a member of Enanta’s audit committee and its nominating and corporate governance committee, effective as of January 1, 2017.
Dr. Russell has over two decades of clinical, regulatory and drug development expertise.
Dr. Russell currently serves as Chief Medical Officer at Innocoll Holdings.
She held executive management positions at TetraLogic Pharmaceuticals, where she held the role of Chief Operating Officer from 2013 through 2016, and at Teva Pharmaceuticals, where she was Senior Vice president and Global Head of Research and Development from 2011-2012.
At Teva, Dr. Russell led a team of over 1,500 and was responsible for all aspects of global drug development. She spent over 10 years at Cephalon where she held positions of increasing responsibility from 2000 -2011, most recently serving as Executive Vice President and Chief Medical Officer.
Dr. Russell currently serves on the Boards of Directors of AMAG Pharmaceuticals, Endocyte Pharmaceuticals and Melmark.
Dr. Russell received a MB.Ch.B. degree from the University of Edinburgh, Scotland, Faculty of Medicine. She is a member of the Royal College of Physicians, UK, and is registered with the General Medical Council, UK. ■
LATEST MOVES FROM Massachusetts
- bluebird bio appoints Mary Lynne Hedley to board
- Welch's names Lesya Lysyj president, US
- Liberty Mutual appoints Gregg Cunningham as vice president
- Voyager Therapeutics appoints Matthew P. Ottmer as COO
- Ocular Therapeutix appoints Michael Goldstein as CMO
More inside POST